Literature DB >> 22790014

Tumor budding in colorectal carcinoma: time to take notice.

Bojana Mitrovic1, David F Schaeffer, Robert H Riddell, Richard Kirsch.   

Abstract

Tumor 'budding', loosely defined by the presence of individual cells and small clusters of tumor cells at the invasive front of carcinomas, has received much recent attention, particularly in the setting of colorectal carcinoma. It has been postulated to represent an epithelial-mesenchymal transition. Tumor budding is a well-established independent adverse prognostic factor in colorectal carcinoma that may allow for stratification of patients into risk categories more meaningful than those defined by TNM staging, and also potentially guide treatment decisions, especially in T1 and T3 N0 (Stage II, Dukes' B) colorectal carcinoma. Unfortunately, its universal acceptance as a reportable factor has been held back by a lack of definitional uniformity with respect to both qualitative and quantitative aspects of tumor budding. The purpose of this review is fourfold: (1) to describe the morphology of tumor budding and its relationship to other potentially important features of the invasive front; (2) to summarize current knowledge regarding the prognostic significance and potential clinical implications of this histomorphological feature; (3) to highlight the challenges posed by a lack of data to allow standardization with respect to the qualitative and quantitative criteria used to define budding; and (4) to present a practical approach to the assessment of tumor budding in everyday practice.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22790014     DOI: 10.1038/modpathol.2012.94

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  98 in total

1.  Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma.

Authors:  Kyuichi Kadota; Yi-Chen Yeh; Jonathan Villena-Vargas; Leonid Cherkassky; Esther N Drill; Camelia S Sima; David R Jones; William D Travis; Prasad S Adusumilli
Journal:  Chest       Date:  2015-09       Impact factor: 9.410

2.  Interobserver variability in the H&E-based assessment of tumor budding in pT3/4 colon cancer: does it affect the prognostic relevance?

Authors:  Benedikt Martin; Eva Schäfer; Elzbieta Jakubowicz; Patrick Mayr; Regina Ihringer; Matthias Anthuber; Gerhard Schenkirsch; Tina Schaller; Bruno Märkl
Journal:  Virchows Arch       Date:  2018-04-06       Impact factor: 4.064

3.  S100A8+ stroma cells predict a good prognosis and inhibit aggressiveness in colorectal carcinoma.

Authors:  Si Li; Fangying Xu; Hui Li; Jing Zhang; Anjing Zhong; Bin Huang; Maode Lai
Journal:  Oncoimmunology       Date:  2016-12-12       Impact factor: 8.110

4.  Enrichment map profiling of the cancer invasion front suggests regulation of colorectal cancer progression by the bone morphogenetic protein antagonist, gremlin-1.

Authors:  George S Karagiannis; Aaron Berk; Apostolos Dimitromanolakis; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2013-04-18       Impact factor: 6.603

5.  Endoscopic Resection of Malignant Colonic Polyps: Why Clinicopathological Correlation (CPC) Is Needed for Optimal Treatment of CRC?

Authors:  David F Schaeffer; Fergal Donnellan
Journal:  Dig Dis Sci       Date:  2015-09       Impact factor: 3.199

6.  A three-tier classification system based on the depth of submucosal invasion and budding/sprouting can improve the treatment strategy for T1 colorectal cancer: a retrospective multicenter study.

Authors:  Hiroshi Kawachi; Yoshinobu Eishi; Hideki Ueno; Tetsuo Nemoto; Takahiro Fujimori; Akinori Iwashita; Yoichi Ajioka; Atsushi Ochiai; Shingo Ishiguro; Tadakazu Shimoda; Hidetaka Mochizuki; Yo Kato; Hidenobu Watanabe; Morio Koike; Kenichi Sugihara
Journal:  Mod Pathol       Date:  2015-02-27       Impact factor: 7.842

7.  Poorly differentiated clusters (PDCs) as a novel histological predictor of nodal metastases in pT1 colorectal cancer.

Authors:  Valeria Barresi; Giovanni Branca; Antonio Ieni; Luca Reggiani Bonetti; Luigi Baron; Stefania Mondello; Giovanni Tuccari
Journal:  Virchows Arch       Date:  2014-04-27       Impact factor: 4.064

8.  Expression patterns of bone morphogenetic protein antagonists in colorectal cancer desmoplastic invasion fronts.

Authors:  George S Karagiannis; Ann Treacy; David Messenger; Andrea Grin; Richard Kirsch; Robert H Riddell; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2014-04-19       Impact factor: 6.603

9.  Interobserver variability amongst gastrointestinal pathologists in assessing prognostic parameters of malignant colorectal polyps: a cause for concern.

Authors:  A Davenport; J Morris; S A Pritchard; E Salmo; M Scott; N Y Haboubi
Journal:  Tech Coloproctol       Date:  2016-08-13       Impact factor: 3.781

10.  Micropapillary colorectal carcinoma: clinical, pathological and molecular properties, including evidence of epithelial-mesenchymal transition.

Authors:  Raul S Gonzalez; Won Jae Huh; Justin M M Cates; Kay Washington; R Daniel Beauchamp; Robert J Coffey; Chanjuan Shi
Journal:  Histopathology       Date:  2016-10-28       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.